The global pharmaceutical giant TOP10 forecast list was released in 2028!

The global pharmaceutical giant TOP10 forecast list was released in 2028!

Source: Bo Ya/Forest

Recently, the well -known American media Evaluate Pharma predicts that by 2028, the top 10 pharmaceutical company ranking will undergo major changes in the top 10 pharmaceutical company. Enterprises may decline.

The top 10 companies in the list are expected to reach US $ 558.6 billion, and 8 of them are expected to sell more than $ 50 billion in sales.

Although Albervi's former "Medicine King" Xiu Meile faced a patented cliff, sales may decline in the next few years, the two new drugs of autoimmune diseases, RinvoQ and Skyrizi, have performed strongly. Roche has become the best -selling pharmaceutical company in the world.

In addition, Evaluate Pharma predicts that the super -star Keytruda in anti -cancer drugs will reach a peak sales of $ 30 billion in 2028, becoming a new generation of medicine kings, and Merhado rankings with the product will further improve.

2028 global pharmaceutical company TOP10 prediction list

Source: Evaluate Pharma

"The King of Immune" Albervi, an independent of 3 heavy anti -inflammatory drugs

It is expected to reach the largest pharmaceutical company

In the next few years, although Albervi will face patented cliffs like other pharmaceutical giants, strong follow -up pipelines will promote the rapid growth of Albewv's prescription sales.

After the self -cultivation of Humira defeated Li Purth's position in the global championship in the prescription medicine in 2012, the label of the "immune king" was closely linked to Albervi. In 2021, Aobavi's annual revenue was 56.2 billion US dollars, a year -on -year increase of 22.7%. Humira broke through the $ 20 billion mark, reaching US $ 20.694 billion, accounting for 37%of the company's revenue. However, HUMIRA will soon face a patent cliff. In 2023, Merrasson's first biological similar medicine in the United States is about to be available. However, the patient's demand for this autoimmune drug is expected to continue for a long time to form a strong "long tail effect".

Moreover, the two immune "supernova" JAK inhibitors RinvoQ and psoriasis products Skyrizi, like a strong new engine, will further consolidate Albervi's position in the field of immunization. The annual report of 2021 shows that Skyrizi's sales were 2.939 billion US dollars, an increase of 84.9%year -on -year; the revenue of oral JAK1 inhibitors RinvoQ reached 1.65 billion US dollars, an increase of more than 100%year -on -year. Abervi is expected to bring $ 15 billion in revenue by 2025.

RinvoQ (UPADACITINIB, Upatinib) is a selective Jak1 inhibitor, which belongs to the second -generation selective JAK inhibitor. As of now, RinvoQ has obtained five indications worldwide: special dermatitis (AD), rheumatoid arthritis (RA), psoriasis arthritis (PSA), ulcerative colitis (UC), and active analgesia Sex spinalitis (AS).

Skyrizi (Risanankizumab, Risa Pearl Mipido) is an IL-23 inhibitor. It has been approved in the United States. It has moderate to severe psoriasis psoriasis and active psoriasis arthritis. Albervi expects that Skyrizi's global sales will exceed $ 7.5 billion in 2025; peak sales are expected to exceed HUMIRA's peak income.

In addition, Albervi has listed the field of tumor as the second largest section other than autoimmune diseases. Its anticancer drug Venclexta is also one of the potential growth pillars of Albervi.

The growth potential of Albervi lies in the diversity of innovative product portfolios. At present, Albervi has become market leaders in many fields such as immunology, oncology, neuroscience, ophthalmology, and aesthetics, and maintains rapid growth in many fields and products.

Oncology giant Roche steadily advances

In the foreseeable future, tumor giant Roche will still perform strongly.

In 2021, Roche's total revenue was 68.7 billion US dollars, an increase of 8.4%year -on -year. Although the "old troidee" Bevarzumab, Telkomoab, and the Lifen categorian Mibab are impacted by biological similar drugs, and the sales revenue is expected to continue to decline. However, the "New Trina" Puffyzumab, Adi Zhuzab, and Bevarzab are expected to make up for the position, which continues to drive the income of the tumor business sector to rise.

In addition, Roche has approved multi-most sclerosis new drugs OCREVUS, PD-L1 antibody Adi Zhuabi, dual-anti-product Emmy Saizabi, ADC products Enmengezumab and other innovative drug growth rates also grow It is considerable that it is the mainstay of Roche's performance. These products are expected to continue to grow in the next six years.

Source: Roche official website

It has to be mentioned that the Tigit therapy of Roche's heavy bet is once known as the next generation of immune tumor drugs, but due to the recent two trials failed, the prospects are now dim. The final result of this therapy will also affect Roche's fate in 2028.

Super heavy bomb -help pharmaceutical giants go further

Merhado

In 2021, Merck's revenue achieved 48.7 billion US dollars. Its star product anti-PD-1 monoclonal KEYTRUDA revenue was 17.2 billion U.S. dollars, an increase of 20%year-on-year, which is the most important source of revenue growth in Merck. And according to Evaluate Pharma, Keytruda will replace Humira of Albervis next year, becoming the world's best -selling prescription medicine. Since then, Keytruda will continue to sell well until the patent expires. Analysts expect Keytruda's sales of more than $ 30 billion in 2028.

Global best -selling drug ranking forecast in 2028

Source: Evaluate Pharma

In addition, Merck HPV vaccine in 2021 reached US $ 5.7 billion, a significant increase of 44%year -on -year. The sales of muscle relaxants BRIDION increased by 28%to $ 1.5 billion. Lynparza's sales of ovarian cancer treatment drugs increased by 36%to $ 989 million. In the next few years, these products are expected to continue to bring good income to Merck.

Astrikan

The rising Asleycom is also due to the rapid growth of its anti -tumor drugs.

The main new medicines of Astraon in the field of tumors include: Tagrisso/Tarissa, Lynparza/Lipzo), ENHERTU (DS-8201) and so on.

Oshitinib is the third -generation EGFR inhibitor, which can be used as auxiliary therapy, first -line therapy and second -line therapy. It is approved in 57, 91 and 91 countries, respectively. The medicine is currently the best -selling single product of Astraikon, with a total annual revenue of US $ 50.015 billion in 2021.

Ora Pali is a PARP inhibitor jointly developed by Astri Akang and Merhado. Indications include ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, respectively, 84, 82, 63, and 60 respectively The state was approved to go public. In 2021, the annual revenue sales reached US $ 2.348 billion, an increase of 30 % year -on -year.

Evaluate Pharma's annual sales of Tagrisso and Lynparza will be doubled between 2021 and 2028.

In addition, the HER2 ADC therapy ENHERTU (Trastuzumab deruxtecan, DS-8201), which was cooperated with the first three-thirds of Astra and the first three, is even more brilliant. At the ASCO 2022 meeting, Professor Modi shared the results of the third phase of clinical research on "HER2 low expression" breast cancer, and won the long -term applause and cheers of the audience. This reaction is extremely rare in professional conferences. The results of this study are expected to change the clinical typing and treatment standards of breast cancer. At the same time, it proves the huge potential of a new generation of antibody puppets.

ENHERTU's first year of sales exceeded $ 200 million, and Astraika scored $ 96 million. The medicine brought $ 214 million in revenue to Astraikon in 2021. Today, from ENHERTU's excellent clinical manifestations, there is still great growth potential in the future.

Strong student

Johnson & Johnson's ranking is expected to continue to rise.

In 2021, Johnson & Johnson Pharmaceutical's revenue was US $ 520.08 billion, an increase of 14.3%year -on -year. Strong income growth mainly comes from Stelara (Uznin Mibetar), which treats autoimmune diseases, treats multi -bone marrowoma, AL starch -like Darzalex (Daref os. Monopoly), IMBRUVICA, TREMFYA (Goodsic monoclonist), Ericada (Apatamine) and other products. Among them, Usuke's sales in 2021 reached $ 9.1 billion, an increase of 18.5%year -on -year.

In the future, Johnson & Johnson is expected to launch another vaccine, which shows that the respiratory tract sympathetic virus (RSV) vaccine phase 2 clinical trial shows that the effectiveness of lower respiratory diseases related to adults and RSVs at the age of 65 and above reached 80%.

In addition to the vaccine, Johnson & Johnson also laid out tumor -related treatment projects. In December 2021, Yang Sen submitted an application for a ready -made T cell therapy for patients with recurrence or refractory multi -myeloma. In March of this year, the BCMA CAR-T therapy carried out by Yang Sen and the legendary biology CARVYKTI (CILTA-CEL) has been approved by the FDA.

Pfizer, Novartis, Beltay Schimibao

Seeking a new growth point

Faced with patented cliffs, if there is no heavy product that can be relayed, the company's ranking will face a decline.

In this forecast, Evaluate Pharma believes that the wealth income brought by COVID-19 will not last long. However, Pfizer can use tens of billions of dollars in these two years to hatch new products, or expand the pipeline through BD to achieve continuous growth.

Although Novartis has gained a variety of innovative products in recent years, she has always lacked super heavy bombs like Humira and Keytruda, which is slightly fatigue. But last year, Nuohua received a $ 20.7 billion accident with Roche shares in his own hands. It may also adopt this strategy to create new revenue growth points.

The main reason for the decline of Belle Schimingbao is the old product pipeline. Its 72%of its 2021 revenue is derived from old products that have been listed for more than 10 years. With the gradual expiration of the patent, BMS will face a violent siege of generic drugs. At the same time, the results of BMS injecting new blood into its pipelines are currently unsatisfactory. The top 10 pharmaceutical giants include Sanofi ($ 50.8 billion) and GlaxoSmith ($ 44 billion). Both companies missed the trend of the COVID-19 vaccine, and they are currently actively expanding the pipelines to find new growth momentum.

At present, in addition to Dupixent (Dupilumab, Dupi Billab), other products have been tepid. However, with a heavy potential bomb with Dupixent, it has also guaranteed the continuous growth of Sanofi's future sales. Dupixent has obtained four indications, including eosinophilic esophagitis (EOE), medium-weight specific dermatitis (AD), asthma, chronic nasal-sinus polyps (CRSWNP). With the continuous increase in clinical indications and the continuous expansion of the market, the drug is expected to become the world's second largest best -selling anti -inflammatory drug after ABBVIE repair. The peak in the future will also be expected to exceed 10 billion Dollar.

Grammot has no heavy bombs, and the sales of mature drugs are shrinking, but fortunately there are many types of drugs. At present, GSK is the best -selling HIV drug Dolita, with sales revenue of US $ 2.588 billion in 2021. Products with annual sales of more than 1 billion US dollars are: Shingrix, COPD Trini therapy Treyingrix (SHINGRIX, COPD Trinity Therapy (Flutin Flipatamon/Umei Cromine/Veran Telo inhaled Plus Misty) and Anti -inflammatory drugs NUCALA (Meipbo Lisaries) and so on.

Enterprise development is like "going against the water to boat, and retreat if not advances." The more replacement of the "medicine king" of the past also represents the prosperity and decline of the enterprise. In the face of patent cliffs, pharmaceutical companies can only maintain vitality and continue to move forward only by continuously developing new product lines or self -research or purchasing.

- END -